Regentis appoints AMI Medical Technologies as exclusive Israeli distributor for GelrinC knee implant
A four-year exclusive deal with minimum purchase commitments covers Israel, with revenue expected from 2027 and talks on HMO reimbursement to follow.
Regentis Biomaterials signed a four-year exclusive distribution agreement with AMI Medical Technologies on 9 November 2026. Under the deal, AMI will commercialise GelrinC, Regentis's knee cartilage repair implant, in Israel.
GelrinC already holds registration with the Israeli Ministry of Health (AMAR) and a CE Mark, so the product can be marketed in Israel without further regulatory approval. The agreement includes minimum purchase commitments. Regentis expects to start recording revenue from the arrangement in 2027.
The two companies also plan to work together to obtain reimbursement coverage from Israeli health maintenance organisations (HMOs). The source does not say when coverage decisions might be made or which HMOs will be approached.
Separately, the U.S. pivotal Phase III trial of GelrinC is continuing. The announcement gave no further detail on that study, and no financial terms of the Israeli deal were provided.
Why it matters
- Registration in Israel (AMAR) and a CE Mark are already in place, so the deal is a commercial step rather than a regulatory one.
- Market-access teams should note that HMO reimbursement is still to be secured and is a precondition for wider uptake in Israel.
- Minimum purchase commitments and a four-year exclusivity period give a fixed commercial framework, with revenue expected from 2027.
- The U.S. Phase III trial continues, so US regulatory status remains separate from this Israeli launch.
Company's press release (SEC filing): Regentis Biomaterials Ltd. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Medline details repair and replace programme for recalled beds, rails, mattresses and accessories
Cingulate nearly done with manufacturing fixes for ADHD drug CTx-1301 ahead of NDA resubmission
Bluejay completes SYMON-II enrolment for Symphony IL-6 sepsis test, eyes 510(k) filing in H1 2027
Philips recalls Azurion 7 M20 over software faults that can halt imaging or stand movement
Game Changer Products recalls all lots of 10 Day Forecast capsules over hidden sildenafil
